Q-omics provides the consensus-scored NTRK1 profile across patient tissues and cancer cell-line models. NTRK1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NTRK1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NTRK1 RNA expression shows 14,587 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where NTRK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTRK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTRK1 survival associations across molecular data types. NTRK1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTRK1 RNA expression–survival associations across cancer types. High NTRK1 expression shows unfavorable associations in UVM, KIRP, KIRC and LGG, but favorable associations in HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NTRK1 RNA expression.
This table summarizes NTRK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NTRK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTRK1 shows lower tumor expression in KIRC, KICH, LUAD, KIRP and LUSC and higher tumor expression in HNSC. The KIRC box plot shows higher NTRK1 RNA expression in normal versus tumor tissue (log2 FC = −0.516, t-test p < 0.001).
This table shows molecular features associated with NTRK1 in patient tissues and cancer cell lines. In patient samples, NTRK1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NTRK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
